Pharmaceutical Registration in Panama: DNFD, the Central American RTCA Framework and Regional Access

Panama is two markets wearing one name, and confusing them is the most common mistake exporters make here.

There is Panama the country — four and a half million people, a decent but modest pharmaceutical market. And there is Panama the crossroads, where the Colón Free Zone moves goods into Central America, the Caribbean and the top of South America. The second one is why most people are interested. It is also the one that gets misunderstood.

Holding stock in Colón is a customs arrangement. It does not let you sell in Panama, and it does not let you sell in any of the countries you are shipping to. Each of those still wants its own registration. Every so often somebody discovers this at a destination border with a container already in motion, and it is not a cheap lesson.

The genuinely good news about Panama is something else entirely: it belongs to a regulatory bloc where one dossier does the work of six.

Medicines in Panama are regulated by the DNFD — Dirección Nacional de Farmacia y Drogas, within the Ministry of Health (Ministerio de Salud, MINSA).

The DNFD is responsible for sanitary registration of medicines, authorisation and inspection of pharmaceutical establishments, import control, and pharmacovigilance.

The DNFD participates as an observer agency at the Pan American Health Organization's Regional Reference Regulatory Authorities meetings, alongside agencies from Ecuador, El Salvador, Paraguay, Peru and Uruguay — a useful indicator that Panama is engaged in regional convergence rather than maintaining an isolated framework.

Like everywhere in the region, you need a locally established representative. The registration cannot sit with a manufacturer abroad — somebody in Panama has to be answerable for it.

The usual trade-off applies. Go through your distributor and it is quick and cheap, but your market position now lives inside that relationship. Set up your own entity or use an independent regulatory representative and it costs more at the start, but you can change commercial partners without losing the country.

Panama adds a wrinkle that is easy to miss. Because so many exporters use the same partner for the Panamanian registration and for Free Zone logistics, that one company can end up holding both your legal access to the market and the physical route your product takes into the rest of the region. That is a lot of leverage to hand to anyone, and it rarely feels like a big decision at the time — it is usually just the convenient option, taken in a hurry, by whoever is closest.

Worth separating the two roles, or at least going in with your eyes open about what you have combined.

Panama applies the Central American Technical Regulation (Reglamento Técnico Centroamericano, RTCA) for pharmaceutical registration requirements. This is the single most useful thing to understand about registering here.

The RTCA for human medicines establishes a harmonised set of registration requirements adopted across the Central American integration bloc — Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica and Panama — approved through COMIECO, the Council of Ministers for Economic Integration.

What harmonisation does and does not give you is the part that is regularly misunderstood:

• It does mean the dossier structure and technical requirements are broadly common across the six countries, so one properly assembled dossier can serve as the basis for filings across the region rather than six separately conceived submissions.
• It does not mean a single registration covers the region. You still file, pay and obtain a registration in each country where you intend to sell.
• It does not merge manufacturing sites. Where the same product is made at different sites, separate registration is required for each.

Expect to provide the CoPP in WHO format, GMP certificate, manufacturing licence, finished product specification and method of analysis, batch Certificate of Analysis, stability data appropriate to the climatic zone, bioequivalence data where applicable, Spanish labelling and artwork, and a legalised power of attorney for the local representative.

A further provision worth noting: within the Central American framework, a certificate issued by a stringent regulatory authority approving the product may be accepted in support of safety and efficacy in certain cases even where that authority is not in the holder's country of origin. Confirm the current position and its applicability to your product with the DNFD before relying on it.

Two distinct mechanisms can reduce the burden of entering Panama and the wider Central American region.

1. The RTCA harmonised framework. Because the six member countries share a common technical requirement set, the marginal cost of adding another Central American market is far lower than assembling a fresh dossier. This argues strongly for treating Central America as a single regional programme rather than as six unrelated opportunities. Costa Rica in particular operates mutual recognition arrangements within this framework.

2. Reliance on established authorities. The Pan American Health Organization designates eight Regional Reference Regulatory Authorities in the Americas — ANMAT (Argentina), ANVISA (Brazil), Health Canada, ISP (Chile), INVIMA (Colombia), CECMED (Cuba), US FDA and COFEPRIS (Mexico). An approval already held with one of these, or with a stringent regulatory authority such as the EMA, can materially change the evidence burden in a smaller market.

Combined, these point to a clear sequencing strategy: secure an anchor approval with a major authority, assemble one RTCA-compliant dossier, then roll it across the Central American bloc. That is a very different cost structure from filing opportunistically, country by country, as enquiries arrive.

The extent of reliance available is at the receiving authority's discretion and varies by product category. Verify before building a timeline on it.

As elsewhere, published review periods and real elapsed time diverge, and the gap is largely explained by deficiency cycles rather than by the authority's stated processing time.

Within the Central American framework, some analytical standards and product samples may be requested after registration is granted, under post-authorisation analysis arrangements — a sequencing detail worth confirming for your product, since it affects when you need physical material available and where it must be held.

Registrations are granted for a fixed term and require renewal. Track renewal dates across all six Central American markets in one place if you are running a regional programme; the failure mode we see most often in multi-country portfolios is a renewal missed in a smaller market that nobody was actively watching.

Plan variations — site changes, specification amendments, artwork updates — as a recurring cost of holding a regional portfolio, not as exceptions.

Foreign-issued documents require authentication before Panamanian authorities will accept them.

Panama is a party to the Hague Apostille Convention, as is India. Where both the issuing and receiving countries are parties, public documents can generally be authenticated by apostille rather than full consular legalisation — faster and cheaper, and worth confirming before arranging consular appointments.

Recurring practical issues:

• CoPP validity periods — obtaining it too early means re-issuing before filing.
• Commercial documents may require notarisation before they qualify for apostille.
• Certified Spanish translation, meeting local formal requirements.
• Exact consistency of legal entity and site names across every document.

If you are filing across several Central American countries, sequence certificate issuance so that one CoPP validity window covers as many filings as possible, rather than obtaining and legalising separate certificates months apart.

Panama has two distinct things going on that are constantly confused, and separating them is essential.

Transit and re-export are not import. Product held in the Colón Free Zone for onward shipment is in a customs regime, not on the Panamanian market. That is a logistics arrangement and it does not require Panamanian sanitary registration — but nor does it give you the right to sell into Panama, or into any onward country. Every destination market still requires its own registration or its own exceptional authorisation. Exporters who treat Free Zone stock as regional market access discover the problem at the destination border.

Placing product on the Panamanian market requires either a sanitary registration from the DNFD or an authorisation under one of the exceptional routes.

As across the region, exceptional import mechanisms exist to cover genuine clinical need that the registered market cannot meet:

• No registered equivalent available for the clinical requirement.
• Shortage or supply interruption of a registered product where continuity of treatment is at risk.
• Public health need or declared emergency.
• Orphan and rare disease products where commercial registration is not viable.
• Clinical trial material, under its own authorisation route.

These authorisations are granted against a specific justification rather than as standing permission, and are normally applied for by the importing institution or licensed importer, not by the foreign manufacturer. Your job is to make their application succeed by supplying complete documentation quickly.

The rule holds here as everywhere: an exceptional route is a legitimate way to meet a real need and to begin a relationship, not a substitute for registration. In Panama there is an added consideration — because the country is a regional hub, an exporter can be tempted to service several Central American markets through repeated exceptional authorisations rather than registering. That is a fragile position, and the RTCA framework makes proper registration across the bloc unusually economic by comparison.

Confirm current requirements and conditions with the DNFD before relying on any of this.

Named patient supply follows the regional pattern: an unregistered medicine may be imported for an individually identified patient, on the responsibility of a treating physician, where no suitable registered alternative exists.

Typically required:

• Prescription from a licensed physician naming the patient.
• Clinical justification for why no registered alternative is suitable.
• Authorisation from the health authority before the consignment moves.
• Quantity limited to the patient's treatment course.
• Batch Certificate of Analysis, provenance documentation, and depending on the case a CoPP.

Compassionate use and expanded access — products still in clinical development supplied outside a trial where no alternative exists — sit under a separate framework from the ordinary import authorisation.

Panama has a specific practical advantage for this work. Its position as the region's logistics hub means air connectivity across Central America, the Caribbean and northern South America is unusually good, and cold chain infrastructure is better than in most neighbouring markets. Where a named patient consignment has to reach a patient in days rather than weeks, routing through Panama is often the fastest option available — including for patients in surrounding countries.

The operational reality is the same as elsewhere: tiny quantities, high urgency, and documentation that has to be right first time because there is rarely a chance to correct it. Many suppliers will not take the work. We do, partly because the hospitals that need it are frequently the same institutions that later run tenders.

Further reading: our global guide to named patient import programmes, our named patient supply service, and our cold chain logistics page for temperature-controlled consignments.

Panama's public pharmaceutical demand runs principally through the Ministry of Health (MINSA) and the social security system, the Caja de Seguro Social (CSS). Between them they represent the bulk of institutional volume, and CSS in particular is a substantial purchaser.

A valid sanitary registration is generally required to bid. Public procurement presupposes registration rather than providing a way around it. A registration timeline cannot be compressed to fit a tender that has already been announced, so if the public channel is your target, the registration is infrastructure you build ahead of demand.

Two structural advantages are specific to Panama and worth planning around.

The RTCA bloc multiplies the return on one dossier. Because Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica and Panama share harmonised registration requirements, a single well-built dossier can support tender participation across six national procurement systems. Very few regions offer that. It changes the economics of institutional supply from six separate projects into one regional programme.

The PAHO Strategic Fund is a parallel route. The Strategic Fund is the Pan American Health Organization's regional pooled-procurement mechanism, through which member states that have signed an agreement with the Organization purchase essential medicines and supplies. Eligibility rests on international qualification — criteria include WHO Prequalification status at the time of tender opening, and approval by regulatory authorities of regional reference — rather than on separate national registration in each purchasing country.

For an exporter holding WHO Prequalification or an approval from a PAHO regional reference authority, the Strategic Fund can open several Latin American public sectors at once. Confirm current eligibility criteria with PAHO, as they are revised periodically.

In every case the technical file decides the outcome before price is opened. Our government and institutional tender supply page sets out what it must contain and why bids fail at technical evaluation.

The documentation burden is not one fixed thing. It scales with the route, and matching the right level to the right route saves both money and months.

The Panamanian conclusion is unusually clear. Because the RTCA framework makes the second through sixth registrations far cheaper than the first, the gap between the exceptional-import route and the properly registered route is narrower here than anywhere else in Latin America. An exporter servicing Central America through repeated special permits is very likely paying more in administration and carrying more risk than one who built a single RTCA dossier and filed it six times.

The failure patterns in Panama and the wider Central American bloc:

• Assuming RTCA harmonisation means one regional registration. It harmonises requirements, not registrations. Budget and plan for a filing in each market.
• Confusing Free Zone presence with market access. Holding stock in Colón does not entitle you to sell into Panama or into any onward market without the relevant registration.
• Local representative appointed casually, then found to control both registration and regional logistics.
• Filing the same product from multiple manufacturing sites without allowing for separate registration per site.
• Expired or mismatched supporting certificates — the most common technical cause of avoidable delay anywhere in the region.
• Stability data not supporting the labelled storage condition for a tropical climatic zone.

The main thing about Panama is that you should probably stop thinking about Panama.

Six countries share these registration requirements. Building one dossier and filing it once, in one country, is leaving most of the value on the table — and the companies that do well here worked that out early and ran Central America as a single programme rather than six unrelated opportunities that happened to arrive in a particular order. Nowhere else in Latin America gives you that.

Second: be honest with yourself about which Panama you are actually pursuing. The Free Zone play and the Panamanian sales play are different projects, with different requirements and different partners, and blurring them is how people end up with product sitting in Colón that they cannot legally sell anywhere.

Third, on the practical side, line up your certificate issuance so one CoPP validity window covers as many of the six filings as it can. Obtaining and legalising the same certificate four separate times, months apart, is pure waste — and it is the kind of waste that only shows up once you are already three markets in.

And be careful about handing one partner both your registration and your logistics. That combination is convenient right up until it isn't.

All of the above describes structure, not current requirements. Check the position with the DNFD and against the current RTCA text, and take local advice, before committing money.